During the past month and over the last year, Biogen’s shares have increased significantly, and Barclays, among others, has initiated coverage of the company. Analysts predict a decline in earnings, despite the rise in share value. Recently, Biogen won FDA breakthrough therapy designation for cutaneous lupus erythematosus as well as the European Commission’s approval for high-dose nusinersen for treating Spinal Muscular Atrophy. It’s worth noting that some evaluations of the company's stock predict faltering long-term returns despite the current increases.
The Q4 2025 earnings report showed strong sales. Biogen is expanding its portfolio after licensing oral C5aR1 antagonist from Vanqua Bio. Notably, Biogen received US availability for LEQEMBI IQLIK (lecanemab-irmb), an Early Alzheimer's treatment. Analysts suggest Biogen is undervalued even after the company has expanded the neurology pipeline with Alcyone buyout, and despite Q4 2025 beating estimates. Biogen also recently closed a $2 billion manufacturing investment deal in North Carolina.
Also worthy to note, that Biogen received priority review in China for Leqembi, and HSBC has downgraded the stock to reduce, despite pipeline progress.
Biogen BIIB News Analytics from Tue, 15 Apr 2025 07:00:00 GMT to Sat, 21 Feb 2026 13:26:32 GMT - Rating 8 - Innovation 7 - Information 5 - Rumor 3
